David J Whitman

US Patent:

6566549, May 20, 2003

Filed:

Dec 15, 1998

Appl. No.:

09/212038

Inventors:

Gary David Greenblatt - Rydal PA
Barry Clifford Lange - Lansdale PA
Michael Damian Bowe - Newtown PA
Richard Foster Merritt - Fort Washington PA
Robert Wilczynski - Yardley PA
Gary Robert Larson - Hatfield PA
Lori Marie Petrovich - Blue Bell PA
David William Whitman - Sumneytown PA

Assignee:

Rohm and Haas Company - Philadelphia PA

International Classification:

C08F 428

US Classification:

560202, 5253303, 5253306, 525338, 525 62, 525315, 525361, 525364, 525378, 525379, 525390, 525560, 525561, 525562, 526 88, 526 89, 526207, 526208, 526209, 526212, 526216, 526227, 526318, 526319, 526324, 526325, 526328, 526 64

Abstract:

A continuous process for oligomers which do not contain, as polymerized units, carboxylic acid-containing monomers and their salts, including the steps of: (1) forming a reaction mixture, substantially free of carboxylic acid-containing monomers and their salts, containing: (i) 0. 5 to 99. 95% by weight of the reaction mixture of at least one ethylenically unsaturated monomer; and (ii) 0. 05 to 25% by weight, based on the weight of the ethylenically unsaturated monomer, of at least one free-radical initiator; and (2) continuously passing the reaction mixture through a heated zone wherein the reaction mixture is maintained at a temperature of at least 150Â C. and a pressure of at least 30 bars for from 0. 1 seconds to 4 minutes to form terminally-unsaturated oligomers. In addition, processes for forming oligomers of vinyl acetate and oligomers of vinyl alcohol are disclosed.

US Patent:

6645562, Nov 11, 2003

Filed:

Jun 27, 2002

Appl. No.:

10/183307

Inventors:

Gary David Greenblatt - Rydal PA 19046
Ward Thomas Brown - North Wales PA 19454
Michael Damian Bowe - Newtown PA 18940
Richard Foster Merritt - Fort Wahsington PA 19034
Ronald Scott Beckley - Gilbertsville PA 19525
Barry Clifford Lange - Landsdale PA 19446-3200
Robert Wilczynski - Yardley PA 19067
David William Whitman - Sumneytown PA 18084
Martha Harbaugh Wolfersberger - Perkasie PA 18944

International Classification:

C09D 500

US Classification:

4273855, 427386, 427387, 427487, 427496, 427508, 427517, 525274, 525286, 525292, 525301, 525303, 525309, 525310, 5253265, 5253277, 5253288, 5253289, 5253294, 5253295, 5253301, 5253302, 5253306, 5253307, 5253331, 5253332, 5253333, 5253335

Abstract:

A method of preparing a curable coating and a method of curing the curable coating are disclosed. The curable composition from which the curable coating is prepared may be applied to the surface of a substrate in neat form or in aqueous medium to produce the coating. Curing of the curable coating may be accomplished by chemical generation of free radicals, by electrochemical generation of free radicals, by electron beam, by photochemical generation of free radicals, or by other electromagnetic irradiation.

US Patent:

7402577, Jul 22, 2008

Filed:

Sep 27, 2002

Appl. No.:

10/491403

Inventors:

Jiabing Wang - Chalfont PA, US
Mark E. Duggan - Schwenksville PA, US
David B. Whitman - Phoenixville PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/56
C07J 3/00

US Classification:

514177, 552611, 552513

Abstract:

Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.

US Patent:

7595337, Sep 29, 2009

Filed:

Feb 6, 2006

Appl. No.:

11/883507

Inventors:

Michael J. Breslin - Drexel Hill PA, US
Paul J. Coleman - Wallingford PA, US
Christopher D. Cox - Harleysville PA, US
Lou Anne Neilson - Sellersville PA, US
David B. Whitman - Phoenixville PA, US

Assignee:

Merck & Co. Inc. - Rahway NJ

International Classification:

A61K 31/4162
C07D 231/54

US Classification:

514411, 5483581

Abstract:

The present invention relates to tricyclic pyrazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

US Patent:

20020082371, Jun 27, 2002

Filed:

Dec 19, 2001

Appl. No.:

10/025642

Inventors:

Gary Greenblatt - Rydal PA, US
Barry Lange - Lansdale PA, US
Michael Bowe - Newtown PA, US
Richard Merritt - Fort Washington PA, US
Robert Wilczynski - Yardley PA, US
Gary Larson - Hatfield PA, US
Lori Petrovich - Blue Bell PA, US
David Whitman - Sumneytown PA, US

International Classification:

C08F004/28

US Classification:

526/227000, 526/088000, 526/328000, 526/064000, 560/202000

Abstract:

A continuous process for oligomers which do not contain, as polymerized units, carboxylic acid-containing monomers and their salts, including the steps of: (1) forming a reaction mixture, substantially free of carboxylic acid-containing monomers and their salts, containing: (i) 0.5 to 99.95% by weight of the reaction mixture of at least one ethylenically unsaturated monomer; and (ii) 0.05 to 25% by weight, based on the weight of the ethylenically unsaturated monomer, of at least one free-radical initiator; and (2) continuously passing the reaction mixture through a heated zone wherein the reaction mixture is maintained at a temperature of at least 150 C. and a pressure of at least 30 bars for from 0.1 seconds to 4 minutes to form terminally-unsaturated oligomers. In addition, processes for forming oligomers of vinyl acetate and oligomers of vinyl alcohol are disclosed. Mixtures of fully saturated and terminally unsaturated oligomers are also disclosed.

US Patent:

20020111448, Aug 15, 2002

Filed:

Dec 19, 2001

Appl. No.:

10/025637

Inventors:

Gary Greenblatt - Rydal PA, US
Barry Lange - Lansdale PA, US
Michael Bowe - Newtown PA, US
Richard Merritt - Fort Washington PA, US
Robert Wilczynski - Yardley PA, US
Gary Larson - Hatfield PA, US
Lori Petrovich - Blue Bell PA, US
David Whitman - Sumneytown PA, US

International Classification:

C08F004/28

US Classification:

526/227000, 526/088000, 526/328000, 526/064000, 560/202000

Abstract:

A continuous process for oligomers which do not contain, as polymerized units, carboxylic acid-containing monomers and their salts, including the steps of: (1) forming a reaction mixture, substantially free of carboxylic acid-containing monomers and their salts, containing: (i) 0.5 to 99.95% by weight of the reaction mixture of at least one ethylenically unsaturated monomer; and (ii) 0.05 to 25% by weight, based on the weight of the ethylenically unsaturated monomer, of at least one free-radical initiator; and (2) continuously passing the reaction mixture through a heated zone wherein the reaction mixture is maintained at a temperature of at least 150 C. and a pressure of at least 30 bars for from 0.1 seconds to 4 minutes to form terminally-unsaturated oligomers. In addition, processes for forming oligomers of vinyl acetate and oligomers of vinyl alcohol are disclosed. Mixtures of fully saturated and terminally unsaturated oligomers are also disclosed.

US Patent:

20040213846, Oct 28, 2004

Filed:

Mar 24, 2004

Appl. No.:

10/808855

Inventors:

Gary Greenblatt - Rydal PA, US
Lyn Hughes - Harleysville PA, US
David Whitman - Harleysville PA, US

International Classification:

A61K009/26
A61K009/14

US Classification:

424/469000

Abstract:

An extended release dosage form and an extended release polymeric dispenser containing polymer-clay nanocomposite are provided. The polymer-clay nanocomposite contains exfoliated clay platelets dispersed in a polymer matrix. The extended release dosage form contains active ingredient in the polymer-clay nanocomposite. The extended release polymeric dispenser contains a reservoir of an active ingredient partially or completely encapsulated by a polymer-clay nanocomposite layer. Also provided are a method of providing release of an active ingredient from the extended release dosage form and a method or providing release of an active ingredient from the extended release polymeric dispenser. The extended release dosage form and the extended release polymeric dispenser are useful for the application of pharmaceutical compounds, agricultural compounds, and perfumes.

US Patent:

20090118200, May 7, 2009

Filed:

May 22, 2006

Appl. No.:

11/920596

Inventors:

Jeffrey M. Bergman - Sellersville PA, US
Paul J. Coleman - Wallingford PA, US
Christopher D. Cox - Harleysville NJ, US
George D. Hartman - Lansdale PA, US
Craig Lindsley - Brentwood TN, US
Swati Pal Mercer - Philadelphia PA, US
Anthony J. Roecker - Blue Bell PA, US
David B. Whitman - Phoenixville PA, US

International Classification:

A61K 38/05
C07D 403/12
C07D 401/14
C07D 413/14
A61K 31/4184
A61P 25/00

US Classification:

514 19, 5483061, 5462737, 544139, 514395

Abstract:

The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.